RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 70 filers reported holding RECRO PHARMA INC in Q4 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $13,000 | -97.3% | 4,700 | -98.0% | 0.00% | -100.0% |
| Q3 2020 | $489,000 | +11.1% | 233,100 | +140.8% | 0.00% | 0.0% |
| Q2 2020 | $440,000 | +633.3% | 96,800 | +1208.1% | 0.00% | – |
| Q1 2020 | $60,000 | -55.6% | 7,400 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $135,000 | -25.0% | 7,400 | -54.9% | 0.00% | – |
| Q3 2019 | $180,000 | -69.2% | 16,400 | -71.5% | 0.00% | -100.0% |
| Q2 2019 | $584,000 | +63.6% | 57,500 | -5.7% | 0.00% | +50.0% |
| Q1 2019 | $357,000 | -34.1% | 61,000 | -20.2% | 0.00% | -33.3% |
| Q4 2018 | $542,000 | -16.5% | 76,400 | -16.3% | 0.00% | 0.0% |
| Q3 2018 | $649,000 | -3.3% | 91,300 | -31.8% | 0.00% | 0.0% |
| Q2 2018 | $671,000 | -4.1% | 133,800 | +110.4% | 0.00% | 0.0% |
| Q1 2018 | $700,000 | +241.5% | 63,600 | +186.5% | 0.00% | +200.0% |
| Q4 2017 | $205,000 | +485.7% | 22,200 | +455.0% | 0.00% | – |
| Q3 2017 | $35,000 | +25.0% | 4,000 | 0.0% | 0.00% | – |
| Q2 2017 | $28,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MAK CAPITAL ONE LLC | 850,129 | $2,423,000 | 0.65% |
| Newtyn Management, LLC | 700,000 | $1,995,000 | 0.46% |
| Portolan Capital Management | 1,293,376 | $3,686,000 | 0.34% |
| Rubric Capital Management LP | 1,076,587 | $3,068,000 | 0.22% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 99,046 | $282,000 | 0.04% |
| Alyeska Investment Group, L.P. | 736,821 | $2,100,000 | 0.03% |
| STEPHENS INC /AR/ | 510,569 | $1,455,000 | 0.03% |
| Clear Harbor Asset Management, LLC | 46,682 | $133,000 | 0.02% |
| WYNNEFIELD CAPITAL INC | 13,000 | $37,000 | 0.02% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 451,301 | $1,286,000 | 0.01% |